Omeros (OMER) Misses Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Omeros Corporation Reports First Quarter 2016 Financial Results
May 10, 2016 7:20 AM EDT-- Conference Call Today at 9:00 a.m. ET --
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the first quarter of 2016, which include:
1Q 2016 revenues were $7.4 million, an 11% increase over 4Q 2015. Net loss in 1Q was $20.5 million, or $0.54 per share, which included $4.7 million ($0.12 per share) of non-cash... MoreLeonard M. Blum Joins Omeros to Lead Business and Commercial Activities
May 10, 2016 7:05 AM EDTSEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced the hiring of Leonard Blum as chief business and commercial officer. Mr. Blum is leading the companys sales, marketing, commercial strategy and planning, and business development, including for OMIDRIA® (phenylephrine and ketorolac injection) 1% / 0.3% and the companys growing pipeline of development-stage programs.
Mr. Blum brings over 28 years of executive and management experience in... More
